Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

The researchers found that 6.5% of adults experienced cost burdens and 3.5% had CCBs during year one; 17.4% and 9.9%, respectively, experienced these outcomes at least once over 4 years. Overall, 24.7 ...

Receipt of educational leaflet also reduces misperception of asymptomatic bacteriuria as urinary tract infection.

Adults with congenital heart disease benefit from routine care at ACHD centers and collaboration with ACHD cardiologists ...

Diagnostic evaluation should follow principle of 'as low as reasonably achievable'; systemic therapy should be deferred until second trimester ...

In modified intention-to-treat analysis, time to linkage to care significantly less for people with HIV in intervention group ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Pediatric patients aged 10 years and older with iron deficiency may now be treated with Accrufer following an expanded FDA approval.

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.